ECSP23070234A - Anti-cd30l antibodies and uses thereof - Google Patents
Anti-cd30l antibodies and uses thereofInfo
- Publication number
- ECSP23070234A ECSP23070234A ECSENADI202370234A ECDI202370234A ECSP23070234A EC SP23070234 A ECSP23070234 A EC SP23070234A EC SENADI202370234 A ECSENADI202370234 A EC SENADI202370234A EC DI202370234 A ECDI202370234 A EC DI202370234A EC SP23070234 A ECSP23070234 A EC SP23070234A
- Authority
- EC
- Ecuador
- Prior art keywords
- cd30l antibodies
- cd30l
- antibodies
- ibd
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163150373P | 2021-02-17 | 2021-02-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP23070234A true ECSP23070234A (es) | 2023-10-31 |
Family
ID=82931610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202370234A ECSP23070234A (es) | 2021-02-17 | 2023-09-14 | Anti-cd30l antibodies and uses thereof |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20240254246A1 (https=) |
| EP (1) | EP4294840A4 (https=) |
| JP (2) | JP7559257B2 (https=) |
| KR (1) | KR20230157356A (https=) |
| CN (2) | CN118047872A (https=) |
| AR (1) | AR124895A1 (https=) |
| AU (1) | AU2022224561A1 (https=) |
| BR (1) | BR112023016445A2 (https=) |
| CA (1) | CA3208060A1 (https=) |
| CL (1) | CL2023002393A1 (https=) |
| CO (1) | CO2023011962A2 (https=) |
| CR (1) | CR20230445A (https=) |
| EC (1) | ECSP23070234A (https=) |
| GE (3) | GEAP202516710A (https=) |
| IL (1) | IL305146A (https=) |
| JO (1) | JOP20230186A1 (https=) |
| MX (1) | MX2023009621A (https=) |
| PE (1) | PE20231680A1 (https=) |
| TW (1) | TW202302637A (https=) |
| WO (1) | WO2022177963A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023512423A (ja) | 2019-12-24 | 2023-03-27 | ジュベナ・セラピューティクス・インコーポレイテッド | 再生性ポリペプチドおよびその使用 |
| WO2022177963A1 (en) | 2021-02-17 | 2022-08-25 | Prometheus Biosciences, Inc. | Anti-cd30l antibodies and uses thereof |
| KR20240029031A (ko) | 2021-06-21 | 2024-03-05 | 쥬베나 테라퓨틱스, 인크. | 재생 폴리펩티드 및 이의 용도 |
| AU2023315888A1 (en) * | 2022-07-25 | 2025-02-06 | Prometheus Biosciences, Inc. | Anti-cd30l antibodies, formulations therefor, and uses thereof |
| WO2024143497A1 (ja) * | 2022-12-28 | 2024-07-04 | 国立大学法人京都大学 | Ｃｄ１５３を標的とする医薬組成物 |
| AR133766A1 (es) * | 2023-09-12 | 2025-10-29 | Amgen Inc | Anticuerpos anti-cd30l y usos de los mismos |
| WO2025075049A1 (ja) * | 2023-10-03 | 2025-04-10 | 国立大学法人京都大学 | ヒトｃｄ１５３を標的とする抗体ならびにキメラ抗原受容体 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DE69334070T2 (de) * | 1992-05-26 | 2007-01-04 | Immunex Corp., Thousand Oaks | Neue zytokine die cd30 binden |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| US6652854B2 (en) * | 2000-08-08 | 2003-11-25 | Immunex Corporation | Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US20080233119A2 (en) | 2003-08-20 | 2008-09-25 | University Of Miami | Compositions and methods for treating inflammatory lung disease |
| SG11201401536QA (en) * | 2011-10-21 | 2014-05-29 | Nestec Sa | Methods for improving inflammatory bowel disease diagnosis |
| CN117264057A (zh) * | 2012-04-27 | 2023-12-22 | 诺和诺德股份有限公司 | 人cd30配体抗原结合蛋白 |
| EP2945865B1 (en) | 2013-01-18 | 2019-01-09 | LORD Corporation | Active vibration control devices, systems, and methods |
| CA2997444A1 (en) * | 2015-09-29 | 2017-04-06 | Amgen Inc. | Asgr inhibitors for reducing cholesterol levels |
| EP3405185A4 (en) | 2016-01-19 | 2019-09-18 | Thomas Blumenthal | BIOMARKERS FOR DOWN SYNDROME AND USES THEREOF |
| ES2962715T3 (es) * | 2018-04-30 | 2024-03-20 | Cedars Sinai Medical Center | Métodos y sistemas para selección y tratamiento de pacientes con enfermedades inflamatorias |
| WO2020096046A1 (ja) | 2018-11-09 | 2020-05-14 | 国立大学法人大阪大学 | 老化関連ｔ細胞を標的とした糖代謝異常の予防または治療用ワクチン |
| WO2022177963A1 (en) | 2021-02-17 | 2022-08-25 | Prometheus Biosciences, Inc. | Anti-cd30l antibodies and uses thereof |
-
2022
- 2022-02-16 WO PCT/US2022/016565 patent/WO2022177963A1/en not_active Ceased
- 2022-02-16 GE GEAP202516710A patent/GEAP202516710A/en unknown
- 2022-02-16 CA CA3208060A patent/CA3208060A1/en active Pending
- 2022-02-16 IL IL305146A patent/IL305146A/en unknown
- 2022-02-16 JP JP2023549602A patent/JP7559257B2/ja active Active
- 2022-02-16 CN CN202410189800.6A patent/CN118047872A/zh active Pending
- 2022-02-16 MX MX2023009621A patent/MX2023009621A/es unknown
- 2022-02-16 BR BR112023016445A patent/BR112023016445A2/pt unknown
- 2022-02-16 AU AU2022224561A patent/AU2022224561A1/en active Pending
- 2022-02-16 TW TW111105667A patent/TW202302637A/zh unknown
- 2022-02-16 GE GEAP202416351A patent/GEAP202416351A/en unknown
- 2022-02-16 AR ARP220100318A patent/AR124895A1/es unknown
- 2022-02-16 US US18/546,955 patent/US20240254246A1/en active Pending
- 2022-02-16 GE GEAP202216351A patent/GEP20257791B/en unknown
- 2022-02-16 EP EP22756817.7A patent/EP4294840A4/en active Pending
- 2022-02-16 PE PE2023002377A patent/PE20231680A1/es unknown
- 2022-02-16 CR CR20230445A patent/CR20230445A/es unknown
- 2022-02-16 KR KR1020237031681A patent/KR20230157356A/ko active Pending
- 2022-02-16 CN CN202280028982.8A patent/CN117255802A/zh active Pending
- 2022-08-26 US US17/822,598 patent/US11866505B2/en active Active
-
2023
- 2023-08-09 JO JOJO/P/2023/0186A patent/JOP20230186A1/ar unknown
- 2023-08-14 CL CL2023002393A patent/CL2023002393A1/es unknown
- 2023-09-08 CO CONC2023/0011962A patent/CO2023011962A2/es unknown
- 2023-09-14 EC ECSENADI202370234A patent/ECSP23070234A/es unknown
- 2023-11-15 US US18/510,511 patent/US12516126B2/en active Active
-
2024
- 2024-09-17 JP JP2024160401A patent/JP2025004013A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GEAP202416351A (en) | 2024-02-12 |
| GEP20257791B (en) | 2025-09-10 |
| CL2023002393A1 (es) | 2024-03-22 |
| BR112023016445A2 (pt) | 2023-12-12 |
| AR124895A1 (es) | 2023-05-17 |
| JP7559257B2 (ja) | 2024-10-01 |
| EP4294840A1 (en) | 2023-12-27 |
| US20240092923A1 (en) | 2024-03-21 |
| GEAP202516710A (en) | 2025-05-13 |
| CA3208060A1 (en) | 2022-08-25 |
| WO2022177963A1 (en) | 2022-08-25 |
| KR20230157356A (ko) | 2023-11-16 |
| US20230060624A1 (en) | 2023-03-02 |
| TW202302637A (zh) | 2023-01-16 |
| US12516126B2 (en) | 2026-01-06 |
| JP2025004013A (ja) | 2025-01-14 |
| CN118047872A (zh) | 2024-05-17 |
| CN117255802A (zh) | 2023-12-19 |
| CR20230445A (es) | 2023-11-14 |
| CO2023011962A2 (es) | 2023-09-29 |
| AU2022224561A1 (en) | 2023-09-28 |
| US11866505B2 (en) | 2024-01-09 |
| JOP20230186A1 (ar) | 2023-08-09 |
| IL305146A (en) | 2023-10-01 |
| PE20231680A1 (es) | 2023-10-19 |
| US20240254246A1 (en) | 2024-08-01 |
| AU2022224561A9 (en) | 2023-10-05 |
| JP2024509746A (ja) | 2024-03-05 |
| MX2023009621A (es) | 2023-10-31 |
| EP4294840A4 (en) | 2025-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP23070234A (es) | Anti-cd30l antibodies and uses thereof | |
| ECSP23070237A (es) | Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof | |
| NZ787680A (en) | Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof | |
| MY191324A (en) | Neutralizing anti-tl1a monoclonal antibodies | |
| CO2022010330A2 (es) | Dosificación de gamma-hidroxibutirato (ghb) | |
| ECSP15038626A (es) | A61k 30/395 | |
| WO2019209995A3 (en) | Optimized anti-tl1a antibodies | |
| MX2019007586A (es) | Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares. | |
| AR113881A1 (es) | Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia | |
| EP3414573A4 (en) | NOVEL ANTI-LAM AND ANTI-PIM6 / LAM MONOCLONAL ANTIBODIES FOR THE DIAGNOSIS AND TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTIONS | |
| CL2020002225A1 (es) | Uso de anticuerpos anti-il-36r para el tratamiento de la enfermedad inflamatoria intestinal | |
| CL2022001016A1 (es) | Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos | |
| BR112014021251A2 (pt) | anticorpos humanos para toxinas de clostridium difficile | |
| MX2020007917A (es) | Derivados de tiofeno no condensados y sus usos. | |
| CO2020005200A2 (es) | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios | |
| MX389847B (es) | Composiciones de ésteres de ácido cannabidiólico y usos de las mismas. | |
| MX2019009185A (es) | Compuesto heterociclico novedoso, su metodo de preparacion y composicion farmaceutica que lo comprende. | |
| CU20200041A7 (es) | Amidas de imidazopiridina sustituidas | |
| MX2019012051A (es) | Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial. | |
| MX2018012538A (es) | Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmaceuticas y metodos para usar los mismos. | |
| SA520412289B1 (ar) | مركبات مثبط الهدف الميكانيكي للراباميسين | |
| EA201790282A1 (ru) | Замещенные бициклические дигидропиримидиноны и их применение в качестве ингибиторов активности нейтрофил-эластазы | |
| MX2025001038A (es) | Anticuerpos anti-cd30l, formulaciones de estos, y uso de los mismos | |
| DOP2023000160A (es) | Anticuerpos anti-cd30l y usos de estos | |
| AR111845A1 (es) | Anticuerpos biespecíficos anti-cgrp / anti-il-23 y usos de los mismos |